Shares of Emergent BioSolutions (NYSE: EBS) were sliding 9.3% lower as of 11:13 a.m. EST on Friday. The decline came after Chardan Capital analyst Keay Nakae downgraded the stock from buy to hold. Nakae set a one-year price target for Emergent Biosolutions of $112, more than 4% below the stock's closing price on Thursday.
Chardan Capital's downgrade came after Emergent BioSolutions announced solid fourth-quarter results on Thursday. The company reported record revenue of $583 million, a 62% year-over-year increase. Emergent posted adjusted earnings per share of $3.67 compared to $1.57 in the prior-year period. Both results easily topped the consensus Wall Street estimates.
Investors shouldn't dwell on what analysts think. Instead, focus on the business prospects for Emergent BioSolutions. And those prospects continue to look quite good.
The company expects to deliver revenue in full-year 2021 of between $1.95 billion and $2.05 billion with adjusted earnings between $475 million and $525 million. The midpoint of the revenue range reflects year-over-year growth of nearly 29%. The midpoint of the adjusted earnings range reflects growth of nearly 18%.
One potential catalyst for the healthcare stock could be on the way soon. Johnson & Johnson could obtain U.S. Emergency Use Authorization (EUA) for its COVID-19 vaccine by the end of February. Emergent BioSolutions has a contract with J&J to manufacture its vaccine.
10 stocks we like better than Emergent BioSolutions
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Emergent BioSolutions wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2020
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.